IgM Antibody to Borrelia burgdorferi (Lyme Disease) by Immunoassay
This test measures the presence of IgM antibodies against *Borrelia burgdorferi*, the bacterium responsible for Lyme disease. These antibodies develop in your blood after infection and can help confirm an active or recent Lyme infection.
["This test helps diagnose Lyme disease by detecting immune system responses to the Lyme bacterium."]
Key facts at a glance
- LOINC
- 111304-2
- Short code
- COXPH2M
- Synonyms
- C burnet Ph2 IgM Msmt Ser
- Category
- chemistry
- Sample
- serum
- Container
- Serum separator tube (SST) or red-top vacutainer tube
- Units
- N/A
- Ref low
- 16
- Ref high
- 1
- Fasting
- false
- Population
- adult
- Sex
- all
- Age range
- 18–65 years
- Method
- Enzyme-linked immunosorbent assay (ELISA) or Indirect Immunofluorescence Assay (IFA) for detection of IgM antibodies against Coxiella burnetii phase 2 antigen
- CPT
- 86638
- SNOMED
- 395124008
- Specimen volume
- 1-2 mL of serum
- Stability
- Stable at 2-8°C for 7 days; for longer storage, freeze at -20°C or below; avoid repeated freeze-thaw cycles
- Hemolysis max
- 500
- Lipemia max
- 1000
- Icterus max
- 500
- TAT
- 24–72 hours
- Order
- routine
What Does This Test Measure?
The test detects IgM antibodies, a type of immune protein your body produces in response to infection. These antibodies appear shortly after infection and can persist for months or years. The test is used to identify if you have an active or recent Lyme infection, though results can vary based on timing since exposure.
How Is the Sample Collected?
A blood sample is drawn from a vein in your arm by a healthcare professional. The blood is processed to separate the serum, where the test is performed.
Why Might This Test Be Ordered?
Your healthcare provider may order this test if you have symptoms like fever, fatigue, rash (e.g., bull’s-eye rash), joint pain, or neurological issues that align with Lyme disease. It’s also used in follow-up testing for suspected Lyme after initial negative results or in cases of persistent symptoms.
What Are Common Symptoms of Lyme Disease?
Lyme disease often starts with a red rash (erythema migrans) at the bite site, followed by flu-like symptoms such as fever, chills, headache, and fatigue. Joint pain, muscle aches, or neurological symptoms (e.g., numbness, memory issues) may also occur later. Symptoms can vary widely and may not always appear immediately.
Reference range
Negative: <1:16 (IFA) or <9 U/mL (ELISA); Equivocal: 1:16-1:32 (IFA) or 9-11 U/mL (ELISA); Positive: >1:32 (IFA) or >11 U/mL (ELISA). Phase 2 IgM antibodies indicate acute Q fever infection.N/A
No fasting required. Patients should inform their healthcare provider of any recent antibiotic use, as early antibiotic therapy may blunt the antibody response. Acute-phase specimens should be collected 2-3 weeks after symptom onset for optimal sensitivity.
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
◆Associated findings1
Short name
IgM Lyme Antibody
Frequently asked questions
When will I get my results back?
Can I have this test if I’ve already been treated for Lyme?
What if my test is positive but I don’t have symptoms?
Sources
- 1
- 2Lab Tests OnlineSource
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy